Form 8-K - Current report:
SEC Accession No. 0000950170-23-049683
Filing Date
2023-09-25
Accepted
2023-09-25 16:00:35
Documents
15
Period of Report
2023-09-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bbio-20230925.htm   iXBRL 8-K 74445
2 EX-10.1 bbio-ex10_1.htm EX-10.1 333530
3 EX-10.2 bbio-ex10_2.htm EX-10.2 166601
4 EX-99.1 bbio-ex99_1.htm EX-99.1 14791
  Complete submission text file 0000950170-23-049683.txt   799222

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bbio-20230925_lab.xml EX-101.LAB 13360
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bbio-20230925.xsd EX-101.SCH 2455
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bbio-20230925_pre.xml EX-101.PRE 10982
9 EXTRACTED XBRL INSTANCE DOCUMENT bbio-20230925_htm.xml XML 4704
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 231275824
SIC: 2834 Pharmaceutical Preparations